CAS: 69954-66-1; 4-(Dimethylamino)Butanoic Acid Hydrochloride

上下游产品

CAS号872-50-4 N-甲基吡咯烷酮(NMP) | CAS号50-00-0 甲醛 | CAS号56-12-2 4-氨基丁酸 | CAS号22041-23-2 4-(二甲基氨基)丁酸乙酯 | CAS号6976-17-6 4-(甲胺)丁酸盐酸盐 | CAS号6300-04-5 N,N-二甲基-Β-丙氨酸 | CAS号6249-56-5 (3-羧丙基)三甲基氯化铵 | CAS号3760-63-2 4-Dimethylamino... | CAS号693-11-8 4-二甲基氨基丁酸盐酸盐

📜N-甲基吡咯烷酮置于盐酸,甲酸体系中,用 水 作为反应溶剂,化学反应 18.5H,反应生成 4-(二甲胺基)丁酸 盐酸盐
参考文献:Preparation Of 3-Carboxy-N,N,N-Trimethylpropanaminium Chloride (γ-Butyrobetaine Hydrochloride)
标题:Preparation Of 3-Carboxy-N,N,N-Trimethylpropanaminium Chloride (γ-Butyrobetaine Hydrochloride)
摘要:
DOI:10.1055/s-1981-29489

专利信息

专利号:US-2024294462-A1
优先权日:2023-02-15
标题:Method for the Synthesis of Ionizable Lipids Using a Doubly Alkylated Intermediate
发明人：SAADATI FARIBA; TRAN HUY; CIUFOLINI MARCO; ATMURI N D PRASAD
权利人:NANOVATION THERAPEUTICS INC
摘要:Provided herein is a method for the preparation of ionizable, cationic amino lipids using a doubly alkylated nucleophilic intermediate to produce a ketone. The ketone, or a corresponding alcohol, is subjected to one or more synthesis steps to add an ionizable moiety thereto. The method can be advantageously employed for the synthesis of unsymmetrical analogues of the above lipids that would be considerably more difficult to make by alternative strategies. The method can also be used to prepare symmetrical ionizable, cationic amino lipids with fewer steps and/or with the use of fewer hazardous chemicals than known synthesis methods.

专利号:US-2008221377-A1
优先权日:2006-06-16
标题 :Methods for synthesis of carotenoids, including analogs, derivatives, and synthetic and biological intermediates
发明人：LOCKWOOD SAMUEL F; TANG PENG CHO; NADOLSKI GEOFF; JACKSON HENRY L; FANG ZHIQIANG; DU YISHU; YANG MIN; GEISS WILLIAM; WILLIAMS RICHARD; BURDICK DAVID; BRAUN CRISTI L
权利人:LOCKWOOD SAMUEL F; TANG PENG CHO; NADOLSKI GEOFF; JACKSON HENRY L; FANG ZHIQIANG; DU YISHU; YANG MIN; GEISS WILLIAM; WILLIAMS RICHARD; BURDICK DAVID; BRAUN CRISTI L
摘要:A method for synthesizing intermediates for use in the synthesis of carotenoid synthetic intermediates, carotenoid analogs, and/or carotenoid derivatives. The carotenoid analog, derivative, or intermediate may be administered to a subject for the inhibition and/or amelioration of any disease that involves production of reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals. In some embodiments, the invention may include methods for synthesizing chemical compounds including an analog or derivative of a carotenoid. Carotenoid analogs or derivatives may include acyclic end groups. In some embodiments, a carotenoid analog or derivative may include at least one substituent. The substituent may enhance the solubility of the carotenoid analog or derivative such that the carotenoid analog or derivative at least partially dissolves in water.

专利号:US-2008207532-A1
优先权日:2004-10-06
标题:Use of Nordihydroguaiaretic Acid Derivatives in the Treatment of Drug Resistant Cancer, Viral and Microbial Infection
发明人：HUANG RU CHIH; HWU JIH RU; HSU MING-HUA; MOLD DAVID E; LEE YUAN C; CHANG CHIH-CHUAN
权利人:UNIV JOHNS HOPKINS
摘要:Compositions and methods for using nordihydroguaiaretic acid (NDGA) derivatives for preventing the expression of MDR-1 gene and the synthesis of PgP protein or reversing multiple drug resistance in cells, and for using NDGA derivatives in combination with additional chemotherapeutic agents to treat drug resistant cancer and infections.

专利号:US-2023113511-A1
优先权日:2020-02-20
标题 :Use of tmava antagonist and system for diagnosing fatty liver or heart failure
发明人：ZHENG LEMIN; WANG DAOWEN; MENG XIANGBAO; ZHAO MINGMING; Li Chenze
权利人:ZHENG LEMIN; PROGLEAD INC
摘要:Use of a N,N,N-trimethyl- 5 -aminopentanoic acid antagonist in the preparation of a medicament for treating fatty liver or heart failure and a system for diagnosing fatty liver or heart failure. New treatment regimens are provided for fatty liver or heart failure. By antagonizing TMAVA, the levels of triglyceride and free fatty acids in the plasma and liver of a patient can be reduced, and at the same time, the inhibition effect of TMAVA on the activity of γ-isopropylbetaine hydroxylase can also be eliminated, and the weakening of free fatty acid mitochondrial β-oxidation caused by the decrease of endogenous carnitine synthesis is avoided. It is thus determined that reducing the ectopic accumulation of fatty acids in the liver and heart is clearly effective in treating fatty liver or heart failure.

专利号:US-2024287015-A1
优先权日:2021-05-28
标题 :Method for Producing an Ionizable Lipid
发明人：CIUFOLINI MARCO A; SAADATI FARIBA; TAM ANTHONY C Y; KUREK DANIEL; WITZIGMANN DOMINIK; KULKARNI JAYESH
权利人:NANOVATION THERAPEUTICS INC
摘要:Provided herein is a method for producing an ionizable lipid that comprises: (i) reacting fatty esters in a Claisen condensation reaction in the presence of a catalyst, the Claisen condensation employing a weak base and carried out at a temperature of between −10 and 60 degrees Celsius to produce a ketoester; (ii) reacting the ketoester produced in step (i) under conditions to produce a ketone from the ketoester in one or more steps via a hydrolysis and decarboxylation of the ketoester; and (iii) preparing the ionizable lipid from the ketone thereof using one or more synthesis steps resulting in an addition of an ionizable head group moiety to (a) the ketone; or (b) an alcohol produced from an optional reduction of the ketone to produce the alcohol, thereby producing the ionizable lipid. The ionizable lipid produced in step (iii) may be formulated in a drug delivery vehicle.

专利号:US-2008096868-A1
优先权日:2004-11-12
标题:1,4 Substituted Pyrazolopyrimidines as Kinase Inhibitors
发明人：SCHMIEDEBERG NIKO; FURET PASCAL; IMBACH PATRICIA; HOLZER PHILIPP
权利人:SCHMIEDEBERG NIKO; FURET PASCAL; IMBACH PATRICIA; HOLZER PHILIPP
摘要:The invention relates to 1,4-substituted pyrazolopyrimidine compounds of the formula I, n npharmaceuticals comprising a 1,4-substituted pyrazolopyrimidine compound, the use of a 1,4-substituted pyrazolopyrimidine compound in the treatment or the use thereof in the manufacture of a pharmaceutical formulation for the treatment of a disease that depends on inadequate activity of a protein kinase, methods of treatment comprising administering a 1,4-substituted pyrazolopyrimidine compound, methods for the manufacture of a novel compound of that class, and novel intermediates and partial steps for their synthesis.